Overview

Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial

Status:
Unknown status

Trial end date:
2020-07-31

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to evaluate the efficacy of the SGLT2 inhibitor dapagliflozin, as compared with standard care of diabetes, on left ventricular (LV) functional change in asymptomatic type 2 diabetes mellitus (DM) patient.

Phase:

Phase 4

Details

Lead Sponsor:

Mackay Memorial Hospital

Treatments:

2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
2,4-thiazolidinedione
Dapagliflozin
Hypoglycemic Agents
Meglitinide
Metformin
Sodium-Glucose Transporter 2 Inhibitors